Basal insulin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic Kidney DiseaseType 1 Diabetes Mellitus

172 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

1

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

112

Basal insulin

AstraZeneca

Phase 3

13

Uloric

Takeda

Preclinical

24

Vemlidy

Gilead

Preclinical

15

Lorelco

Sanofi

Preclinical

16

Sovaldi

Gilead

Preclinical

17

Glucotrol

Pfizer

Preclinical

18

Activase

Roche

Preclinical

—9

Flomax

Sanofi

Preclinical

—10

Tradjenta

Boehringer Ingelheim

Preclinical

1Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 2 Diabetes9 trials

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Completed·Sanofi·Phase 3·NCT00715624·496 enrolled

Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments

Completed·Novo Nordisk··NCT04809311·156 enrolled

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Completed·Novo Nordisk·Phase 3·NCT01850615·323 enrolled

Show 6 more trials

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Completed·AstraZeneca·Phase 4·NCT00467649·112 enrolled

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

Completed·AstraZeneca··NCT02917057·6,024 enrolled

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Completed·Sanofi·Phase 3·NCT00866658·311 enrolled

Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

Completed·AstraZeneca··NCT01060059·888 enrolled

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Withdrawn·Eli Lilly·Phase 4·NCT04864977

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom Sensor

Active, not recruiting·DDexCom, Inc.·Phase 1·NCT07681375·45 enrolled

Type 2 Diabetes Mellitus3 trials

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Completed·Merck & Co.·Phase 3·NCT02033889·621 enrolled

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Completed·Sanofi·Phase 4·NCT02941367·184 enrolled

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Completed·Sanofi·Phase 1·NCT02803918·23 enrolled

Type 1 Diabetes2 trials

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed·MMannkind Corporation·Phase 4·NCT05904743·141 enrolled

Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes

Completed·MMayo Clinic·Phase 4·NCT00276393·22 enrolled

Type 1 Diabetes Mellitus2 trials

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

Recruiting·Eli Lilly·Phase 1·NCT06280703·118 enrolled

INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes

Recruiting·MMannkind Corporation·Phase 2·NCT07224321·100 enrolled

Chronic Kidney Disease1 trial

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Completed·LLMC Diabetes & Endocrinology Ltd.··NCT06236672·348 enrolled

6 more indications

Medication1 trial

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Unknown status·—··NCT05161429·550,000 enrolled

Pediatrics1 trial

Afrezza® INHALE-1 Study in Pediatrics

Completed·MMannkind Corporation·Phase 3·NCT04974528·319 enrolled

Outcome1 trial

Clinical Outcomes of Exenatide Versus Basal Insulin

Completed·AstraZeneca··NCT02987348·18,000 enrolled

Diabetes1 trial

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Completed·UUniversity of California, San Francisco·N/A·NCT02846233·22 enrolled

Metformin1 trial

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

Completed·Novartis·Phase 3·NCT01871558·42 enrolled

Effectiveness1 trial

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

Completed·AstraZeneca··NCT02974244·7,000 enrolled

Details

Drug Info

Related News